The percentage of patients with a thyroid nodule of indeterminate cytology with a recommendation for a multi-gene next-generation sequencing panel (ThyroSeq V2) in Final Pathology Report, followed with direct communication to Patient/Ordering or Attending Provider regarding recommendation.